The aromatization of androgens by primary monolayer cultures of fetal rat hypothalamus.

Aromatization of [3H]androstenedione and [3H]19-hydroxyandrostenedione to [3H]estrone has been demonstrated to occur in one to two week old primary monolayer cultures of fetal rat hypothalamus. Three times more estrone is produced from 19-hydroxyandrostenedione than from androstenedione in four day incubations. Cultures treated with cytosine arabinoside have 50% less cellular protein and produce three times more estrone from either substrate than untreated cultures. Time course experiments using cultures treated with cytosine arabinoside indicate that aromatization of 19-hydroxyandrostenedione is linear for three days and can be quantitatively measured within the first two to eight hours of incubation.

Localization of aromatase and 5 alpha-reductase to neuronal and non-neuronal cells in the fetal rat hypothalamus.

Experiments were designed to identify the neural cell type(s) responsible for the aromatization and 5 alpha-reduction of androgens in the rat hypothalamus. Primary cultures of fetal rat hypothalamic cells, which had enhanced neuronal morphology, were treated at various times after plating with kainic acid (KA), a neurotoxic agent which selectively destroys neuronal cells. Neuronal morphology was disrupted in a time (0-6 days)- and dose (10(-4)-10(-2) M)-dependent fashion after KA treatment, with no apparent change in the appearance of the flattened, underlying non-neuronal cells. KA treatment for 4 days decreased aromatization by 94% in a dose-dependent fashion (10(-4)-10(-2) M KA), while 5 alpha-reduction declined by no more than 25%. A 6-day time course with 10(-3) M KA showed a dramatic decline in aromatization and no alteration in 5 alpha-reduction. In control experiments, substance P, a neuronal peptide, declined after KA treatment while the activity of glutamine synthetase, a glial enzyme, did not change. We conclude from these results that aromatase is localized primarily to neuronal cells in the hypothalamus while 5 alpha-reductase is confined primarily to non-neuronal cells.

Studies on the role of catecholamines in the regulation of the developmental pattern of hypothalamic aromatase.

Experiments were conducted to study the regulation of the developmental pattern of aromatase in the forebrain of the perinatal rat. Two experimental designs were used: aromatase measured in primary cultures of fetal hypothalamic cells and in cell-free preparations of forebrain tissue excised at varying ages. In cultured cells, aromatase decreased logarithmically at a slow rate (t1/2 = 7.8 days). Norepinephrine caused a pronounced dose (4 x 10(-6) M) and time-dependent (2-6 days) drop in aromatase without affecting the levels of 5 alpha-reductase or substance P. In isolated tissue, aromatase activity was compared with the concentrations of norepinephrine and dopamine in the forebrain of males vs females at different perinatal ages and in discrete forebrain areas at postnatal day 4. In no case was a sex difference in catecholamines seen. An overall developmental decline in aromatase was associated with developmental increases in catecholamine levels. Acute treatment with the beta-agonist, isoproterenol, had no effect on brain aromatase activity.

Symbiosis therapy: the potential of using human protozoa for molecular therapy.

The concept of symbiosis is proposed as a disease therapy model. It is hypothesized that protozoa that live naturally in human tissues can be genetically modified for the production and delivery of therapeutic proteins. Approximately 30 identified species of protozoa live in a variety of human tissues, both intracellularly and extracellularly. Leishmania, one species of human protozoa, has been genetically altered for conditional auxotrophy and has shown no pathology in both mouse and nonhuman primate safety tests. Several species of protozoa have been transfected with a variety of genes and have successfully manufactured active foreign proteins. Protozoa have biochemical mechanisms to glycosylate proteins. Human protozoa have evolved sophisticated mechanisms for evading immune rejection and can sometimes persist for the lifetime of the host. Symbiosis therapy does not involve genetic alteration of the host and is potentially fully reversible. Research on treating genetic diseases is currently ongoing. For example, there is a group of more than 40 genetic diseases, lysosomal storage diseases, which result from defects in lysosomal enzymes primarily in macrophages. Leishmania specifically targets the lysosomal compartment of the macrophage and therefore may be the optimal vector for treatment of many of these diseases.

Primary cultures of dispersed hypothalamic cells from fetal rats: morphology, electrical activity, and peptide content.

Cultures prepared from dispersed fetal hypothalamic tissue have cells which can be identified as neurons by their morphology and electrical activity. The elongation of neuritic processes in these cultures is increased by treatment with 1-beta-D arabinofuranosylcytosine (ara-C). Hypothalamic cultures have measurable quantities of immunoreactive substance P and neurotensin, and the neurons can accumulate (3H)GABA.

Release of immunoreactive somatostatin from hypothalamic cells in culture: inhibition by gamma-aminobutyric acid.

Primary cultures of dispersed hypothalamic cells were prepared from embryonic rats to study the release of immunoreactive somatostatin. The immunoreactive somatostatin content of these cultures increased during the first 2 weeks after plating and was readily measurable for several weeks thereafter; this material was characterized by gel permeation and reverse-phase chromatography. Depolarization of the cells with 60 mM K+ or with veratridine resulted in a calcium-dependent release of immunoreactive somatostatin which cochromatographed with synthetic somatostatin on reverse-phase chromatography. Tetrodotoxin blocked the veratridine-evoked release. However, even in the absence of exogenous stimuli, immunoreactive somatostatin was released by the cells into the medium. More than 70% of this tonic release was found to be calcium dependent and to be inhibited by tetrodotoxin, indicating that spontaneous electrical activity in the cultures leads to a release of immunoreactive somatostatin. gamma-Aminobutyric acid inhibited the tonic release of immunoreactive somatostatin and this was reversed by bicuculline. These findings support the hypothesis that gamma-aminobutyric acid inhibits somatostatin release in vivo.